Projects per year
Personal profile
Education
- 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1994 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2018- Dean, College of Pharmacy, Taipei Medical University
- 2017- Director, Biomedical Commercialization Center, Taipei Medical University
- 2015- Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
- 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
- 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
- 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Awards
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
Research Interests
- Discovery and Development of small molecular compounds towards IND
- Structure optimization through rational drug design and intelligent modification
- Medicinal Chemistry
Fingerprint Dive into the research topics where Jing-Ping Liou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 11 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Lysine-specific histone demethylase 1 抑制劑的研發
2/1/20 → 1/31/21
Project: A - Government Institution › b - Ministry of Science and Technology
開發阻斷神經類固醇生合成與雄性素接受器活性的新穎藥物以避免癌症抗藥性
1/1/20 → 12/31/20
Project: A - Government Institution › d - Ministry of Education
Synthetic and Medicinal Utility of Organometallics in the Development of Anticancer Epigenetic Inhibitors: Applications and Explorations( I )( I )(1/2)
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
亞太生醫矽谷精準醫療旗艦計畫-臺北醫學大學合作案
1/1/19 → 12/1/19
Project: A - Government Institution › a - National Health Research Institutes
Research Output
Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)
Liu, Y. M., Kuo, C. N. & Liou, J. P., Jan 1 2020, (Accepted/In press) In : Expert Opinion on Therapeutic Patents.Research output: Contribution to journal › Review article
CK1δ as a potential therapeutic target to treat bladder cancer
Lin, Y. C., Chen, M. C., Hsieh, T. H., Liou, J. P. & Chen, C. H., Apr 15 2020, In : Aging. 12, 7, p. 5764-5780 17 p.Research output: Contribution to journal › Article
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., Sep 15 2020, In : European Journal of Medicinal Chemistry. 202, 112633.Research output: Contribution to journal › Comment/debate
Open Access
Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))
Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., Jun 15 2020, In : European Journal of Medicinal Chemistry. 196, 112329.Research output: Contribution to journal › Comment/debate
Open Access
Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))
Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., Sep 1 2020, In : European Journal of Medicinal Chemistry. 201, 112404.Research output: Contribution to journal › Comment/debate